Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years
- 1 June 2020
- journal article
- research article
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 20 (6), 578-583
- https://doi.org/10.1111/ggi.13919
Abstract
Aim Opportunities to treat older patients with hepatitis C virus infection have increased. We investigated the efficacy and safety of glecaprevir/pibrentasvir in patients with HCV infection aged >= 75 years. Methods We retrospectively evaluated 131 patients with hepatitis C virus infection treated with glecaprevir/pibrentasvir at nine institutions in Japan. The patients were divided into two groups according to their age: the elderly group (n= 43, aged >= 75 years) and younger group (n= 88, aged = 75 years.Geriatr Gerontol Int 2020; center dot center dot: center dot center dot-center dot center dot.This publication has 29 references indexed in Scilit:
- Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosisThe Esophagus, 2018
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionThe New England Journal of Medicine, 2018
- Interferon-Free Therapy in Elderly Patients With Advanced Liver DiseaseThe American Journal of Gastroenterology, 2017
- Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patientsEuropean Journal of Gastroenterology & Hepatology, 2017
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosisJournal of Hepatology, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013The Lancet, 2016
- Epidemiology and outcomes of hepatitis C infection in elderly US VeteransJournal of Viral Hepatitis, 2016
- Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderHepatology, 2016
- The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010Journal of Hepatology, 2014